Melanoma Clinical Trials

Showing 521-540 of 705 trials

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

NCT01253564

This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases. Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.

Malignant Melanoma

Hoffmann-La Roche24 participantsStarted Nov 2010

Lausanne, Switzerland • Zurich, Switzerland

COMPLETED

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

NCT02143999

This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation. Patients will be treated per the locally approved therapeutic options in clinical practice. The observation period for each patient will be up to 24 months.

Malignant Melanoma

Hoffmann-La Roche403 participantsStarted Jun 2014

Chieti, Abruzzo, Italy • Bari, Apulia, Italy • Naples, Campania, Italy +21 more locations

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

Related Searches

Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA)

Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis

Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma

A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients

Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma